Read the signal early, non-invasively, and at scale.
Instead of waiting for symptoms, we capture digital biomarkers the body gives off long before, and read them together with AI. No blood draw, no scanner, no clinic visit.
Four things the approach is built around.
Non-invasive by design
No blood draw, no scanner, no clinic. Lower cost and far broader reach than any invasive pathway.
Predictive digital biomarkers
Designed to predict disease development in places where invasive methods give no early signal at all.
High-quality data capture
Multi-stream capture engineered for the data quality that early detection demands.
Improves with every test
An AI platform designed to get sharper with each additional session it sees.
Capture, analyse, act.
One pathway from a home session to a specialist decision, and where indicated, to therapy.
Deep Diagnose
A clinician prescribes a session for patients aged 45+ and high-risk individuals. At home, on a smartphone, five biomarker streams are captured at once.
AI engine
A multi-modal model reads all five streams together and produces a neurocognitive risk score and a specialist report for the prescribing neurologist.
Deep Therapy
Where indicated, the neurologist prescribes daily neurotraining, with periodic specialist review.
Two products on one platform.
Deep Diagnose finds the signal. Deep Therapy acts on it. Both run on a standard smartphone, both are non-invasive, and both report into the prescribing specialist.
Early, accurate diagnosis
- Five biomarker streams captured in a single session
- Risk score and specialist report to the prescribing doctor
- Output shared with the doctor, the patient and the patient's family
- Gamified, easy to use, unlimited tests
Monitoring & self-management
- Continuous neurocognitive status monitoring
- Periodic specialist review via the clinician dashboard
- Gamified, easy to use, non-invasive
All five biomarker streams are live today. Commercial launch in Belgium and the Netherlands is targeted for Q4 2027.
The impact we are building toward.
System impact
Our objective is to bring a screening episode under €100, against a conventional specialist pathway costing thousands of euros, making nationwide screening financially feasible.
Patient & social impact
Earlier detection is designed to keep people independent in their own homes for longer, easing the load on hospitals, care homes and families.
Environmental impact
No equipment, no hospital infrastructure, no travel. A home-based assessment carries a far lower CO₂ footprint per episode than any traditional pathway.